Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Susan Abushakra"'
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 5, p 2727 (2024)
New data suggest that the aggregation of misfolded native proteins initiates and drives the pathogenic cascade that leads to Alzheimer’s disease (AD) and other age-related neurodegenerative disorders. We propose a unifying single toxin theory of br
Externí odkaz:
https://doaj.org/article/48c253a0bc224020801967a7a28ef76d
Publikováno v:
Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-10 (2020)
Abstract The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful efficacy in clinical trials. We ev
Externí odkaz:
https://doaj.org/article/797fdf7f5bf44e9b914b8df3d89edae8
Autor:
Susan Abushakra, Anton P. Porsteinsson, Marwan Sabbagh, Luc Bracoud, Joel Schaerer, Aidan Power, John A. Hey, David Scott, Joyce Suhy, Martin Tolar, for the Alzheimer's Disease Neuroimaging Initiative
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 6, Iss 1, Pp n/a-n/a (2020)
Abstract Introduction Hippocampal volume (HV) and cortical thickness are commonly used imaging biomarkers in Alzheimer's disease (AD) trials, and may have utility as selection criteria for enrichment strategies. Atrophy rates of these measures, in th
Externí odkaz:
https://doaj.org/article/589be485fd064eec9e19303e021541e6
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 12, p 6355 (2021)
A large body of clinical and nonclinical evidence supports the role of neurotoxic soluble beta amyloid (amyloid, Aβ) oligomers as upstream pathogenic drivers of Alzheimer’s disease (AD). Recent late-stage trials in AD that have evaluated agents ta
Externí odkaz:
https://doaj.org/article/0853907e948d4ba58a9e9bb1c45e643f
Autor:
John Hey, Susan Abushakra, Kaj Blennow, Philip Scheltens, Jakub Hort, Katerina Sheardova, Niels Prins, Sterre Rutgers, Paul Dautzenberg, Ladislav Pazdera, Patrick Kesslak, Rosalind Mandelbaum, Aidan Power, Martin Tolar
Publikováno v:
Tuesday, April 25.
Autor:
Susan Abushakra, Rosalind Mandelbaum, Jerome Barakos, Philip Scheltens, Anton P. Porsteinsson, David Watson, Emer MacSweeney, Marwan Sabbagh, Earvin Liang, Patrick Kesslak, Joyce Suhy, Aidan Power, John Hey, Martin Tolar
Publikováno v:
Monday, April 24.
Autor:
Susan Abushakra, John Hey, Kaj Blennow, Philip Scheltens, Eric M. Reiman, Jakub Hort, Katerina Sheardova, Sterre M. Rutgers, Niels D. Prins, Paul Dautzenberg, Ladislav Pazdera, Aidan Power, Martin Tolar
Publikováno v:
Alzheimer's & Dementia. 18
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 6355, p 6355 (2021)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
A large body of clinical and nonclinical evidence supports the role of neurotoxic soluble beta amyloid (amyloid, Aβ) oligomers as upstream pathogenic drivers of Alzheimer’s disease (AD). Recent late-stage trials in AD that have evaluated agents ta
Autor:
Sunil S Dhawan, Domenico Vitarella, Fauad Hasan, Susan Abushakra, Wajdie Ahmad, Steve G Yoelin
Publikováno v:
Plastic and Reconstructive Surgery. 142:847e-855e
Botulinum neurotoxins, which are widely used commercially for therapeutic and cosmetic applications, have historically belonged to serotypes A and B. Serotype E has a distinct profile with a faster onset and shorter duration of effect. EB-001 is a pr
Publikováno v:
Alzheimer's Research & Therapy
Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-10 (2020)
Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-10 (2020)
The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful efficacy in clinical trials. We evaluated t